Pharmakogenomik in der Frauenheilkunde

@article{Huber2002PharmakogenomikID,
  title={Pharmakogenomik in der Frauenheilkunde},
  author={J. Huber and C. Schneeberger and Marion Noe and C. Tempfer},
  journal={Gyn{\"a}kologisch-geburtshilfliche Rundschau},
  year={2002},
  volume={43},
  pages={53 - 65}
}
Leider besteht für diesen Artikel keine Zusammenfassung. Als Einstieg stellen wir den Textanfang zur Verfügung. Mehr als ein Jahrzehnt dauert bereits die wissenschaftliche Auseinandersetzung zwischen deutschen und österreichischen Endokrinologen bzw. Biochemikern, ob eine individuelle Hormonersatztherapie (HRT) sinnvoll ist und wie sie konkret aussehen soll. Dieses Thema wird nicht nur durch rezente Untersuchungen [1] aktualisiert, die klar belegen, dass die behandelten Frauen zu einem hohen… Expand
2 Citations
Adrenopause und Dehydroepiandrosteron: Pharmakotherapie versus Substitution
  • A. Römmler
  • Medicine
  • Gynäkologisch-geburtshilfliche Rundschau
  • 2003
Hintergrund: Die Adrenopause ist als alterstypische partielle Nebennierenrindeninsuffizienz durch erniedrigte Blutspiegel von Dehydroepiandrosteron (DHEA) und DHEA-Sulfat (DS) bei unverändertemExpand
Anti-Aging oder ‘Better Aging’ – Ein Beitrag zur Alterungsprävention?
Anti-Aging will die Qualität der zweiten Lebenshälfte so beeinflussen, dass chronische Gesundheitsschäden auch im höheren Alter bei hoher Lebensqualität vermieden werden können. So soll auch aufExpand

References

SHOWING 1-10 OF 125 REFERENCES
Androgene für Frauen
TLDR
Die gegenwartige Datenlage erlaubt keine generelle Anwendung of Androgenen bei der Frau, auserdem stehen z. Expand
CYP17 genetic polymorphism in endometrial cancer: are only steroids involved?
TLDR
It is demonstrated that A2/A2 CYP17 genotype, considered on the basis of initial breast cancer studies as 'unfavorable', was under-represented in endometrial cancer group (odds ratio 0.48, 95% confidence interval 0.25-0.89) that confirmed results of two other recent investigations. Expand
Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis
TLDR
It is concluded that the thrombosis risk of HRT may particularly affect women with prothrombotic mutations, and efforts to avoid HRT in women with increased risk of thromBosis are advisable. Expand
Polychlorinated biphenyls, cytochrome P4501A1 polymorphism, and postmenopausal breast cancer risk.
  • K. Moysich, P. Shields, +7 authors C. Ambrosone
  • Biology, Medicine
  • Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • 1999
TLDR
PCB body burden may modify the effect of the polymorphism on postmenopausal breast cancer risk through increased CYP1A1 enzyme induction or by activation by specific PCB congeners. Expand
Progression of human breast cancers to the metastatic state is linked to genotypes of catechol-O-methyltransferase.
TLDR
The findings suggest that the allele encoding for low activity COMT may contribute to the progression of breast cancer. Expand
CYP2D6 Genotyping in Patients on Psychoactive Drug Therapy
TLDR
It is suggested that the CYP2D6 genotyping appears to be useful for predicting risks for side effects of psychoactive drugs in schizophrenic patients, but their usefulness should be further explored. Expand
A rare CYP19 (aromatase) variant may increase the risk of breast cancer.
TLDR
The data suggest that the CYP19 gene may be involved as a low penetrance gene in breast cancer susceptibility. Expand
Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women.
TLDR
The results suggest that among postmenopausal hypertensive women, the association between HRT use and MI risk differed between those with and without the prothrombin 20210 G-->A variant. Expand
Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women.
TLDR
The results suggest that among postmenopausal hypertensive women, the association between HRT use and MI risk differed between those with and without the prothrombin 20210 G→A variant. Expand
Interaction of estrogen replacement therapy with the thrombophilic 20210 G/A prothrombin gene mutation for atherothrombotic vascular disease: a cross-sectional study of 275 hyperlipidemic women.
TLDR
It is suggested that the 20210 G/A prothrombin gene mutation should be measured in all women on ERT or before beginning ERT to identify those heterozygous for the thrombophilic prothrome gene mutation in whom ERT is contraindicated because of increased risk for ATCVD and thromboembolism. Expand
...
1
2
3
4
5
...